Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer-Reference-Cited by-同舟云学术

Prostate-specific membrane antigen in circulating tumor cells is a new poor prognostic marker for castration-resistant prostate cancer

Published:2020-01-27 Issue:1 Volume:15 Page:e0226219
ISSN:1932-6203
Container-title:PLOS ONE
language:en
Short-container-title:PLoS ONE

Author:

Nagaya Naoya,Nagata Masayoshi^ORCID,Lu Yan,Kanayama Mayuko,Hou Qi,Hotta Zen-u,China Toshiyuki,Kitamura Kosuke,Matsushita Kazuhito,Isotani Shuji,Muto Satoru,Sakamoto Yoshiro,Horie Shigeo^ORCID

Publisher

Public Library of Science (PLoS)

Subject

Multidisciplinary

Reference32 articles.

1. Sequential use of novel therapeutics in advanced prostate cancer following docetaxel chemotherapy;A Omlin;Ther Adv Urol,2014

2. Cancer of the prostate: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up;C Parker;Ann Oncol,2015

3. Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study;CJ Ryan;Lancet Oncol,2015

4. Enzalutamide in metastatic prostate cancer before chemotherapy;TM Beer;N Engl J Med,2014

5. Blood-Based Cancer Biomarkers in Liquid Biopsy: A Promising Non-Invasive Alternative to Tissue Biopsy;J Marrugo-Ramirez;Int J Mol Sci,2018

Cited by 31 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Intersecting pathways: The role of hybrid E/M cells and circulating tumor cells in cancer metastasis and drug resistance;Drug Resistance Updates;2024-09

2. Liquid Biopsy in the Clinical Management of Cancers;International Journal of Molecular Sciences;2024-08-06

3. Prostate-specific membrane antigen-PET/CT may result in stage migration in prostate cancer: performances, quantitative analysis, and potential criticism in the clinical practice;Nuclear Medicine Communications;2024-04-27

4. Detecting androgen receptor (AR), AR variant 7 (AR-V7), prostate-specific membrane antigen (PSMA), and prostate-specific antigen (PSA) gene expression in CTCs and plasma exosome-derived cfRNA in patients with metastatic castration-resistant prostate cancer (mCRPC) by integrating the VTX-1 CTC isolation system with the QIAGEN AdnaTest;BMC Cancer;2024-04-16

5. The Detection and Negative Reversion of Circulating Tumor Cells as Prognostic Biomarkers for Metastatic Castration-Resistant Prostate Cancer with Bone Metastases Treated by Enzalutamide;Cancers;2024-02-13